[1] |
Vincent, J.L.; Rello, J.; Marshall, J.; Silva, E.; Anzueto, A.; Martin, C.D.; Moreno, R.; Lipman, J.; Gomersall, C.; Sakr, Y.; Reinhart, K.; Investigators, E.I.G.O. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009, 302, 2323–2329.
|
[2] |
Wong, G.; Briscoe, S.; Adnan, S.; McWhinney, B.; Ungerer, J.; Lipman, J.; Roberts, J.A. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob. Agents. Chemother. 2013, 57, 6165–6170.
|
[3] |
Zhou, J.J.; Bai, Y.J.; Wang, X.; Yang, J.; Fu, P.; Cai, D.M.; Yang, L.C. A simple risk score for prediction of sepsis associated-acute kidney injury in critically ill patients. J. Nephrol. 2019, 32, 947–956.
|
[4] |
Sime, F.B.; Stuart, J.; Butler, J.; Starr, T.; Wallis, S.C.; Pandey, S.; Lipman, J.; Roberts, J.A. A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration. Int. J. Antimicrob. Agents. 2018, 52, 506–509.
|
[5] |
Zelenitsky, S.A.; Ariano, R.E.; Zhanel, G.G. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J. Antimicrob. Chemother. 2011, 66, 343–349.
|
[6] |
Udy, A.A.; Varghese, J.M.; Altukroni, M.; Briscoe, S.; McWhinney, B.C.; Ungerer, J.P.; Lipman, J.; Roberts, J.A. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012, 142, 30–39.
|
[7] |
Kovar, A.; Costa, T.D.; Derendorf, H. Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis. J. Pharm. Sci. 1997, 86, 52–56.
|
[8] |
Tsai, D.; Stewart, P.; Goud, R.; Gourley, S.; Hewagama, S.; Krishnaswamy, S.; Wallis, S.C.; Lipman, J.; Roberts, J.A. Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis. Int. J. Antimicrob. Agents. 2016, 48, 748–752.
|
[9] |
Roberts, J.A.; Lipman, J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 2009, 37, 840–851. quiz859.
|
[10] |
Neves, D.V.; Vieira, C.P.; Rocha, A.; Lanchote, V.L. Therapeutic doses of eltrombopag do not inhibit hepatic BCRP in healthy volunteers: intravenous ceftriaxone as a model. J. Pharm. Pharm. Sci. 2018, 21, 236–246.
|
[11] |
Dong, W.C.; Zhang, J.F.; Hou, Z.L.; Jiang, X.H.; Zhang, F.C.; Zhang, H.F.; Jiang, Y. The influence of volume ratio of ultrafiltrate of sample on the analysis of non-protein binding drugs in human plasma. Analyst. 2013, 138, 7369–7375.
|
[12] |
Li, J.M.; Shi, Q.W.; Jiang, Y.; Liu, Y. Pretreatment of plasma samples by a novel hollow fiber centrifugal ultrafiltration technique for the determination of plasma protein binding of three coumarins using acetone as protein binding releasing agent. J. Chromatogr. B. 2015, 1001, 114–123.
|
[13] |
Kotani, A.; Hirai, J.; Hamada, Y.; Fujita, J.; Hakamata, H. Determination of ceftriaxone concentration in human cerebrospinal fluid by high-performance liquid chromatography with UV detection. J. Chromatogr. B. 2019, 1124, 161–164.
|
[14] |
Zhao, Y.L.; Cudkowicz, M.E.; Shefner§, J.M.; Krivickas, L.; David, W.S.; Vriesendorp, F.; Pestronk, A.; Caress, J.B.; Katz, J.; Simpson, E.; Rosenfeld, J.; Pascuzzi, R.; Glass, J.; Rezania, K.; Harmatz, J.S.; Schoenfeld, D.; Greenblatt, D.J. Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. J. Clin. Pharmacol. 2014, 54, 1180–1187.
|
[15] |
Akl, M.A.; Ahmed, M.A.; Ramadan, A. Validation of an HPLC-UV method for the determination of ceftriaxone sodium residues on stainless steel surface of pharmaceutical manufacturing equipments. J. Pharm. Biomed. Anal. 2011, 55, 247–252.
|
[16] |
Kauss, T.; Marchivie, M.; Phoeung, T.; Gaubert, A.; Désiré, A.; Tonelli, G.; Boyer, C.; Langlois, M.H.; Cartwright, A.; Gomes, M.; White, N.; Gaudin, K. Preformulation studies of ceftriaxone for pediatric non-parenteral administration as an alternative to existing injectable formulations. Eur. J. Pharm. Sci. 2017, 104, 382–392.
|
[17] |
Harvey, B.; Johnson, T.N.; Yeomanson, D.; Mulla, H.; Mayer, A.P. Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. Perfusion. 2014, 29, 32–38.
|